PFE · Healthcare

PFIZER INC

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-09-23

• Drug Pricing PolicyImportance 44 · Surprise 60
  Pfizer has entered a new agreement with the U.S. Department of Health and Human Services involving the sharing of overseas pricing revenue. The arrangement could affect future profitability and international pricing…
• Oncology Portfolio GrowthImportance 36 · Surprise 40
  Pfizer’s newer and recently acquired medicines grew 18% year over year, with oncology products from the Seagen portfolio serving as a key growth driver. Padcev was identified as an important product helping offset…
• Product Launch and TransitionImportance 31 · Surprise 42
  Pfizer is refocusing its commercial model on newer and acquired medicines while reducing exposure to its COVID-19 franchise. The strategy redirects spending toward selected markets and products as newer offerings…
• Strategic Portfolio RefocusImportance 31 · Surprise 42
  Pfizer is restructuring its commercial model around newer and acquired medicines while reducing exposure to its COVID-19 franchise. Chief International Commercial Officer Alexandre de Germay said spending has been…
• Revenue Performance and MixImportance 30 · Surprise 40
  Pfizer’s revenue has been flat as sales of its COVID-19 products continue to decline. Newer and recently acquired medicines increased 18% year over year, led in part by products obtained through the Seagen acquisition.…
• Competition and Market ShareImportance 17 · Surprise 24
  BridgeBio reported that its acoramidis product, marketed as Attruby, outperformed Pfizer's tafamidis product Vyndamax in a real-world study. Attruby received U.S. Food and Drug Administration approval in November 2024…

News · 2026-09-22

• Guidance / OutlookImportance 75 · Surprise 60
  Pfizer’s 2026 revenue guidance was reported at $61.5 billion. The guidance increase was attributed to strength in the non-COVID portfolio and prior acquisitions. COVID-19 product sales guidance was reduced, while…
• Guidance and OutlookImportance 75 · Surprise 60
  Third-party reports state that Pfizer raised its 2026 revenue guidance to $61.5 billion. The outlook is supported by non-COVID portfolio strength, acquired products, and new-product ramps, while COVID-19 product sales…
• Product Launch and TransitionImportance 68 · Surprise 58
  New and acquired products accounted for 21.2% of Pfizer’s revenue and were growing 18% year over year. Pfizer is emphasizing cancer, vaccines, and obesity treatments as core areas for portfolio renewal and post-COVID…
• Strategic InitiativesImportance 68 · Surprise 58
  Pfizer is shifting its growth strategy away from COVID-19 products toward new and acquired medicines, vaccines, and oncology products. Acquired and launched products accounted for 21.2% of revenue and grew 18% year…
• Strategic Cost SavingsImportance 64 · Surprise 42
  Pfizer’s operational efficiency programs target $9.7 billion of cost savings through 2029. The savings are expected to support continued research and development investment, debt reduction and the dividend. The program…
• Cost Realignment ProgramImportance 64 · Surprise 42
  Pfizer's operational efficiency programs target $9.7 billion of cost savings through 2029. The reported savings objective is material relative to the company's revenue and is intended to support continued research and…
• Revenue Performance and MixImportance 60 · Surprise 40
  Acquired and launched products represented 21.2% of Pfizer’s revenue and grew 18% year over year. Pfizer expects a significant decline in COVID-19-related revenue as new medicines, vaccines and oncology products…
• Drug Pricing PolicyImportance 47 · Surprise 60
  Analyst reporting identified the rollout of most-favored-nation Medicaid pricing as a factor clouding Pfizer's near-term outlook. The policy could affect U.S. Medicaid pricing and revenue for products subject to the…
• COVID Product Demand DeclineImportance 44 · Surprise 24
  Pfizer is shifting away from COVID-19 products as COVID-related revenue is expected to decline significantly. The portfolio transition reflects lower demand for Comirnaty and other pandemic products after the peak…
• Liquidity and Debt PositionImportance 25 · Surprise 6
  Pfizer’s leverage ratio was reported at 2.7x. The leverage level and patent-expiry risks through fiscal 2028 were cited as constraints on dividend increases. Planned cost savings are expected to support deleveraging…
• Dividends and Capital ReturnImportance 25 · Surprise 6
  Pfizer was reported to have a dividend yield of approximately 6.2%, including a cited 6.22% yield. Free cash flow was described as covering the dividend. Dividend increases were considered unlikely until later this…

News · 2026-09-21

• Guidance and OutlookImportance 75 · Surprise 60
  Third-party reporting states Pfizer is $1.5 billion ahead of its original 2026 base-business guidance. Management is targeting $9.7 billion of cost savings by 2029, which the report says should support dividend…
• Cost Realignment ProgramImportance 64 · Surprise 42
  Pfizer targets $9.7 billion in cost savings by 2029. The savings program is intended to support dividend coverage through the company’s patent cliff. Pfizer also expects the savings to preserve funding for research and…
• Licensing / Collaboration DealsImportance 30 · Surprise 42
  Pfizer entered an in-licensing deal with Medicus Pharma for the CD228V antibody-drug conjugate (ADC). The transaction followed Pfizer’s reprioritization of the asset after its Seagen acquisition, and Medicus obtained…

News · 2026-09-20

• Drug Pricing PolicyImportance 37 · Surprise 42
  Pfizer agreed to share a portion of increased overseas drug revenue with the U.S. Department of Health and Human Services (HHS) under a “most favored nation” contract. The agreement is intended to ensure that higher…

News · 2026-09-19

• Acquisition / Partnership / DivestitureImportance 40 · Surprise 42
  Novartis India acquired Pfizer’s Minipress and Minipress (prazosin) trademarks and related intellectual property rights in India for USD 150 million. The transaction gives Novartis India full ownership of the brands in…

News · 2026-09-18

• Regulatory Approval MilestonesImportance 31 · Surprise 42
  Health Canada authorized Pfizer and BioNTech’s Omicron XFG-adapted COMIRNATY vaccine for people aged 6 months and older. The vaccine is intended for the 2026–2027 season and targets the Omicron XFG lineage. Pfizer…
• Comirnaty Regulatory ApprovalImportance 31 · Surprise 42
  Health Canada authorized Pfizer and BioNTech’s Omicron XFG-adapted COMIRNATY vaccine for individuals aged 6 months and older. The 2026–2027 formulation targets the Omicron XFG lineage and aligns with public-health…

News · 2026-09-14

• Cost Realignment ProgramImportance 64 · Surprise 42
  Pfizer reportedly cut costs by $7.2 billion, an amount materially above the company’s $451 million revenue threshold. The cost program is described as part of management’s response to lower COVID-19 demand and broader…
• DividendsImportance 40 · Surprise 42
  Pfizer's dividend yield was reported at 6.19% on September 14, 2026. Management has committed to maintaining the dividend despite a patent cliff affecting key drugs. The report cited substantial long-term debt and a…
• Patent Exclusivity ExpiriesImportance 38 · Surprise 24
  Pfizer faces a patent cliff affecting key drugs, adding pressure to demand for established products. The reported loss of exclusivity risk is discussed together with declining COVID-19 product demand as a major…
• Product / Drug Pipeline ProgressImportance 31 · Surprise 42
  Pfizer is directing investor attention toward pipeline catalysts in oncology and obesity treatments. Reported priorities include GLP-1 therapies and new products intended to offset COVID-19 demand declines and the…
• Strategic Obesity InitiativeImportance 31 · Surprise 42
  Pfizer is reportedly prioritizing obesity treatments, including GLP-1 therapies, as part of its future growth strategy. The obesity focus is being positioned alongside oncology pipeline catalysts and new-product…
• China Pipeline AcquisitionsImportance 31 · Surprise 42
  Pfizer reportedly plans selective acquisitions of early-stage assets, with particular interest in China. The initiative is intended to strengthen the pipeline as the company faces COVID-19 revenue declines and patent…
• Guidance and OutlookImportance 31 · Surprise 42
  Third-party reporting says Pfizer expects new products, acquisitions, and its pipeline to support growth from 2029. The outlook is driven by oncology and obesity programs, including GLP-1 therapies, while COVID-19…
• COVID Product Demand DeclineImportance 26 · Surprise 24
  Pfizer continues to face lower demand for COVID-19 products, creating a material headwind for its commercial portfolio. Third-party reporting identifies declining COVID revenue as a key challenge alongside the…
• Trade Policy and TariffsImportance 7 · Surprise 6
  Pfizer reportedly addressed tariff and pricing concerns as major headwinds eased in 2026. The reporting does not identify the tariff measures, affected jurisdictions, products, or quantified financial impact. Any…

News · 2026-09-13

• Litigation and Legal RiskImportance 64 · Surprise 42
  Pfizer is pursuing payment in a dispute involving Poland and Romania over more than 90 million unwanted COVID-19 vaccine doses. The contracts are valued at approximately $2 billion, creating a material potential…
• Product Demand TrendsImportance 64 · Surprise 42
  Pfizer is pursuing payment under pandemic-era contracts covering more than 90 million unwanted COVID-19 vaccine doses. The counterparties are Poland and Romania, where demand for the contracted shots has fallen…

News · 2026-09-12

• Product / Drug Pipeline ProgressImportance 38 · Surprise 42
  Medicus Pharma CEO Raza Bokhari highlighted a co-development and licensing opportunity with Pfizer for a CD228-targeted antibody-drug conjugate. The collaboration includes $2 million in funding and supports Medicus…
• Licensing / Collaboration DealsImportance 38 · Surprise 42
  Pfizer is pursuing a co-development and licensing opportunity with Medicus Pharma for a CD228-targeted antibody-drug conjugate. The collaboration includes $2 million in funding for Medicus Pharma. The partnership…

News · 2026-09-10

• Licensing / Collaboration DealsImportance 31 · Surprise 42
  Pfizer has selected its first development field for Novavax’s Matrix-M adjuvant platform. The collaboration could generate milestone payments for combination-vaccine trials and manufacturing-technology transfer,…

News · 2026-09-07

• Licensing / Collaboration DealsImportance 52 · Surprise 42
  Pfizer granted Medicus Pharma an exclusive, sublicensable global license for PF-08046031, also known as CD228V. The early clinical-stage antibody-drug conjugate targets melanotransferrin and is intended for oncology…

News · 2026-09-03

• Licensing / Collaboration DealsImportance 52 · Surprise 42
  Pfizer granted Medicus Pharma an exclusive, sublicensable global license for PF-08046031, also known as CD228V. The early clinical-stage antibody-drug conjugate targets melanotransferrin and is intended for oncology…
• Revenue Performance and MixImportance 41 · Surprise 32
  Pfizer reported second-quarter 2026 revenue of $15.03 billion, exceeding the Zacks consensus estimate. Non-COVID revenue growth and sales from newly launched and acquired products drove the quarterly beat.…
• Comirnaty Regulatory ApprovalImportance 41 · Surprise 60
  The FDA approved Pfizer and BioNTech’s XFG-adapted COMIRNATY vaccine for the 2026–2027 season. The formulation is intended for adults aged 65 and older and people aged 5–64 with high-risk underlying conditions. The…
• COVID Product Demand DeclineImportance 26 · Surprise 24
  Pfizer continues to face weakening demand for its COVID-19 products, including Comirnaty, as the pandemic-related revenue contribution normalizes. Third-party reporting identifies lower COVID product sales as a key…

News · 2026-09-02

• Revenue Performance and MixImportance 41 · Surprise 32
  Pfizer reported second-quarter 2026 revenue of $15.03 billion, exceeding the Zacks consensus estimate. Non-COVID revenue growth and sales from newly launched and acquired products drove the quarterly beat.…

News · 2026-09-01

• CFO Leadership TransitionImportance 25 · Surprise 42
  A September 1, 2026 report identified a CFO transition at Pfizer as one of several CFO changes associated with stock rallies of 10% to 12%. The report attributed the positive market reaction to the companies naming…

News · 2026-08-27

• Comirnaty Regulatory ApprovalImportance 47 · Surprise 60
  The U.S. Food and Drug Administration approved Pfizer and BioNTech’s supplemental Biologics License Application for the 2026–2027 COMIRNATY XFG-adapted COVID-19 vaccine on August 27, 2026. The vaccine targets the XFG…

News · 2026-08-26

• Guidance / OutlookImportance 44 · Surprise 60
  Third-party reporting says Pfizer increased its revenue guidance following strong second-quarter results. The report does not quantify the revised revenue outlook or specify the applicable fiscal timeframe. It says…
• Revenue Performance and MixImportance 23 · Surprise 24
  Pfizer reported strong second-quarter results and increased its revenue guidance, although the article does not provide the revised guidance amount. The company is projected to experience revenue shrinkage as older…

News · 2026-08-25

• Guidance / OutlookImportance 46 · Surprise 60
  Pfizer provided full-year 2026 EPS guidance following second-quarter results that exceeded revenue and earnings expectations. Third-party reporting characterizes the guidance as consistent with a mature…

News · 2026-08-24

• Guidance / OutlookImportance 47 · Surprise 60
  Third-party coverage reports that Pfizer raised its 2026 guidance following second-quarter results. The reported outlook incorporates continued declines in COVID-related revenue and generic competition. Pfizer is…
• Revenue Performance and MixImportance 37 · Surprise 6
  Pfizer reported second-quarter 2026 revenue of $15.03 billion, exceeding earnings expectations. Core product sales offset declines in COVID-related revenue during the quarter. Generic competition also contributed to…
• Product / Drug Pipeline ProgressImportance 31 · Surprise 42
  Pfizer is advancing a Lyme disease vaccine candidate, indicating continued development of new preventive-care products. The company is also expanding into China’s obesity-treatment market. The report presents these…
• Strategic Obesity InitiativeImportance 31 · Surprise 42
  Third-party reporting states that Pfizer is expanding into China’s obesity-treatment market. The initiative adds a China-focused geographic expansion to Pfizer’s obesity pipeline strategy. The digest does not specify…
• COVID Product Demand DeclineImportance 18 · Surprise 24
  Third-party reporting states that Pfizer’s COVID-related revenue is declining. The decline is being balanced by sales of core products, according to the report. This indicates continued demand normalization for…

News · 2026-08-22

• Depo-Provera Litigation SettlementImportance 58 · Surprise 42
  Pfizer agreed to a confidential settlement program covering plaintiffs’ Depo-Provera meningioma lawsuits. The program could involve more than US$1.20 billion in compensation, making it a material legal and cash-flow…
• Patent Exclusivity ExpiriesImportance 36 · Surprise 42
  Third-party reporting identified three notable Pfizer patent expirations expected through the end of 2028. These exclusivity losses create a medium-term risk of generic or biosimilar competition and potential revenue…

News · 2026-08-21

• Product / Drug Pipeline ProgressImportance 31 · Surprise 42
  Pfizer’s oncology-focused mRNA pipeline received positive investor attention following reported positive Phase 3 results for an mRNA melanoma treatment. The development milestone supports Pfizer’s strategy of using…
• DividendsImportance 13 · Surprise 6
  Pfizer declared a quarterly dividend of $0.43 per share. The dividend was reported to produce an annual yield of 6.2%. The payout is attracting income-oriented investors despite patent-cliff and legal-settlement risks.

News · 2026-08-20

• Depo-Provera Litigation SettlementImportance 47 · Surprise 60
  Pfizer established a settlement program covering approximately 5,000 federal lawsuits alleging that Depo-Provera is associated with intracranial meningioma. The program could address most of the more than 6,200 pending…

News · 2026-08-19

• DividendsImportance 13 · Surprise 6
  Pfizer declared a quarterly dividend of $0.43 per share. The dividend was reported alongside second-quarter earnings of $0.77 per share. Third-party coverage cited an approximately 6.3% dividend yield, but did not…